- Home
- OCCI vs PBYI Comparison
OCCI vs PBYI Comparison
Compare OCCI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCCI
- PBYI
- Stock Information
- Founded
- OCCI N/A
- PBYI 2010
- Country
- OCCI United States
- PBYI United States
- Employees
- OCCI N/A
- PBYI N/A
- Industry
- OCCI Trusts Except Educational Religious and Charitable
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- OCCI Finance
- PBYI Health Care
- Exchange
- OCCI Nasdaq
- PBYI Nasdaq
- Market Cap
- OCCI 160.5M
- PBYI 175.7M
- IPO Year
- OCCI N/A
- PBYI N/A
- Fundamental
- Price
- OCCI $6.25
- PBYI $3.46
- Analyst Decision
- OCCI
- PBYI Strong Buy
- Analyst Count
- OCCI 0
- PBYI 1
- Target Price
- OCCI N/A
- PBYI $7.00
- AVG Volume (30 Days)
- OCCI 115.8K
- PBYI 314.4K
- Earning Date
- OCCI 12-11-2023
- PBYI 07-31-2025
- Dividend Yield
- OCCI 24.32%
- PBYI N/A
- EPS Growth
- OCCI N/A
- PBYI 143.51
- EPS
- OCCI N/A
- PBYI 0.77
- Revenue
- OCCI N/A
- PBYI $232,709,000.00
- Revenue This Year
- OCCI N/A
- PBYI N/A
- Revenue Next Year
- OCCI $10.19
- PBYI N/A
- P/E Ratio
- OCCI N/A
- PBYI $4.47
- Revenue Growth
- OCCI N/A
- PBYI 2.68
- 52 Week Low
- OCCI $5.47
- PBYI $2.23
- 52 Week High
- OCCI $10.15
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- OCCI 51.26
- PBYI 50.88
- Support Level
- OCCI $6.21
- PBYI $3.36
- Resistance Level
- OCCI $6.30
- PBYI $3.68
- Average True Range (ATR)
- OCCI 0.07
- PBYI 0.12
- MACD
- OCCI 0.02
- PBYI -0.01
- Stochastic Oscillator
- OCCI 82.76
- PBYI 48.84
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation primarily through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.